Biology Reference
In-Depth Information
at the same time. Samples may also be diluted in buffer A
before administration to the desired conductivity (i.e., keep in
mind that the conductivity of PBS is ~15 mS/cm).
25. The chromatography buffer system used was selected based on
the literature to maximize adenovirus particle stability [
21
].
26. Purity of the final viral products are high as revealed by
OD
260/280
chromatography absorbance ratios (1.3), electron
microscopy and electrophoretic analyses [
16
].
References
1. Sprangers MC, Lakhai W, Koudstaal W,
Verhoeven M, Koel BF, Vogels R et al (2003)
Quantifying adenovirus-neutralizing antibod-
ies by luciferase transgene detection: address-
ing preexisting immunity to vaccine and gene
therapy vectors. J Clin Microbiol 41:5046-
5052
2. Aste-Amezaga M, Bett AJ, Wang F, Casimiro
DR, Antonello JM, Patel DK et al (2004)
Quantitative adenovirus neutralization assays
based on the secreted alkaline phosphatase
reporter gene: application in epidemiologic
studies and in the design of adenovector vac-
cines. Hum Gene Ther 15:293-304
3. Bru T, Salinas S, Kremer EJ (2010) An update
on canine adenovirus type 2 and its vectors.
Viruses 2:2134-2153
4. Soudais C, Laplace-Builhe C, Kissa K, Kremer
EJ (2001) Preferential transduction of neurons
by canine adenovirus vectors and their efficient
retrograde transport in vivo. FASEB J
15:2283-2285
5. Peltekian E, Garcia L, Danos O (2002)
Neurotropism and retrograde axonal transport
of a canine adenoviral vector: a tool for target-
ing key structures undergoing neurodegenera-
tive processes. Mol Ther 5:25-32
6. Alcayaga-Miranda F, Cascallo M, Rojas JJ,
Pastor J, Alemany R (2010) Osteosarcoma
cells as carriers to allow antitumor activity of
canine oncolytic adenovirus in the presence of
neutralizing antibodies. Cancer Gene Ther
17:792-802
7. Smith BF, Curiel DT, Ternovoi VV, Borovjagin
AV, Baker HJ, Cox N et al (2006)
Administration of a conditionally replicative
oncolytic canine adenovirus in normal dogs.
Cancer Biother Radiopharm 21:601-606
8. Hemminki A, Kanerva A, Kremer EJ,
Bauerschmitz GJ, Smith BF, Liu B et al (2003)
A canine conditionally replicating adenovirus
for evaluating oncolytic virotherapy in a synge-
neic animal model. Mol Ther 7:163-173
9. Bouet-Cararo C, Contreras V, Fournier A,
Jallet C, Guibert JM, Dubois E et al (2011)
Canine adenoviruses elicit both humoral and
cell-mediated immune responses against rabies
following immunisation of sheep. Vaccine
29:1304-1310
10. Henderson H, Jackson F, Bean K, Panasuk B,
Niezgoda M, Slate D et al (2009) Oral immu-
nization of raccoons and skunks with a canine
adenovirus recombinant rabies vaccine.
Vaccine 27:7194-7197
11. Hu R, Zhang S, Fooks AR, Yuan H, Liu Y, Li
H et al (2006) Prevention of rabies virus infec-
tion in dogs by a recombinant canine adenovi-
rus type-2 encoding the rabies virus
glycoprotein. Microbes Infect 8:1090-1097
12. Hu RL, Liu Y, Zhang SF, Zhang F, Fooks AR
(2007) Experimental immunization of cats
with a recombinant rabies-canine adenovirus
vaccine elicits a long-lasting neutralizing anti-
body response against rabies. Vaccine
25:5301-5307
13. Liu Y, Zhang S, Ma G, Zhang F, Hu R (2008)
Efficacy and safety of a live canine adenovirus-
vectored rabies virus vaccine in swine. Vaccine
26:5368-5372
14. Dormond E, Perrier M, Kamen A (2009)
From the first to the third generation adenovi-
ral vector: what parameters are governing the
production yield? Biotechnol Adv 27:133-
144
15. Fernandes P, Peixoto C, Santiago VM, Kremer
EJ, Coroadinha AS, Alves PM (2013)
Bioprocess development for canine adenovirus
type 2 vectors. Gene Ther 20(4):353-360
16. Segura MM, Puig M, Monfar M, Chillon M
(2012) Chromatography purification of canine
adenoviral vectors. Hum Gene Ther Methods
23(3):182-197
